Abstract: The present disclosure relates to a steering joint assembly comprising an axle beam, a first king pin rigidly mounted on the axle beam, a steering knuckle, and a first spherical plain bearing rotatably connecting the first king pin to the steering knuckle.

Abstract: The present document relates to a mechanical assembly, comprising: a first roller bearing including an inner race, an outer race and a plurality of rolling elements, wherein an axis of rotation of the first roller bearing defines a first axial direction oriented horizontally or inclined with respect to the vertical direction, a source of lubricant configured to deliver lubricant to the first roller bearing, and at least one movable element disposed adjacent to the first roller bearing on a first side of the first roller bearing in the first axial direction, wherein the rolling elements of the first roller bearing are tapered and their larger diameter ends point towards the at least one movable element, and/or wherein axes of rotation of the rolling elements of the first roller bearing are inclined with respect to the the first axial direction so that centrifugal forces generated inside the first roller bearing are configured to transport lubricant towards the at least one movable element.

Abstract: A cooling system for a power take-off is proposed. The cooling system comprises a housing including a first chamber for at least partially accommodating a power take-off and a second chamber for at least partially accommodating an axle assembly including an axle shaft, and at least one passive heat conducting element arranged between the first chamber and the second chamber, the at least one passive heat conducting element being configured to provide thermal communication between the first chamber and the second chamber. Furthermore, a transmission assembly for a vehicle is proposed, the transmission assembly comprising the cooling system.

Abstract: The methods and compositions of the disclosure provide for novel therapeutic compounds to treat obesity and aspects related thereto. Embodiments of the disclosure relate to oligonucleotide therapeutic (ONT) agents targeting miR-22 miRNA for the treatment of human obesity and related cardiometabolic disorders. Accordingly, aspects of the disclosure relate to modified nucleic acids, including locked nucleic acids, ethylene-bridged nucleotides, peptide nucleic acids, phosphorodiamidate morpholino oligonucleotides, and or a 5?(E)-vinyl-phosphonate modification.

Abstract: Disclosed herein, inter alia, are methods of use and composition of novel inhibitors that target the Smac binding site of a variety of inhibitor of apoptosis proteins that contain a Bir domain, including XIAP, cIAP1, cIAP2, or other IAP proteins.

Abstract: Disclosed herein are valve assemblies, such as for use in a tire inflation system, the valve assemblies comprising: a first fluid port and a second fluid port fluidly connectable with one another via a fluid passage; a first valve having an open position and a closed position, the first valve in its closed position blocking the fluid passage and in its open position unblocking the fluid passage; a second valve having an open position and a closed position, the second valve in its closed position blocking the fluid passage and in its open position unblocking the fluid passage; and a control volume fluidly connected or fluidly connectable with the first fluid port via a flow restrictor, wherein the first valve, the second valve and the control volume are configured such that a fluid pressure in the control volume biases each of the first valve and the second valve toward their closed position.

Abstract: Disclosed herein are valve assemblies, such as for use in a tire inflation system, the valve assemblies comprising: a first fluid port and a second fluid port fluidly connectable with one another via a fluid passage; a first valve having an open position and a closed position, the first valve in its closed position blocking the fluid passage and in its open position unblocking the fluid passage; a second valve having an open position and a closed position, the second valve in its closed position blocking the fluid passage and in its open position unblocking the fluid passage; and a control volume fluidly connected or fluidly connectable with the first fluid port via a flow restrictor, wherein the first valve, the second valve and the control volume are configured such that a fluid pressure in the control volume biases each of the first valve and the second valve toward their closed position.

Abstract: The methods and compositions of the disclosure provide for novel therapeutic compounds to treat obesity and aspects related thereto. Embodiments of the disclosure relate to oligonucleotide therapeutic (ONT) agents targeting miR-22 miRNA for the treatment of human obesity and related cardiometabolic disorders. Accordingly, aspects of the disclosure relate to modified nucleic acids, including locked nucleic acids, ethylene-bridged nucleotides, peptide nucleic acids, phosphorodiamidate morpholino oligonucleotides, and/or a 5?(E)-vinyl-phosphonate modification.

Abstract: Disclosed herein, inter alia, are methods of use and composition of novel inhibitors that target the Smac binding site of a variety of inhibitor of apoptosis proteins that contain a Bir domain, including XIAP, cIAP1, cIAP2, or other IAP proteins.